145 related articles for article (PubMed ID: 9565579)
1. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells.
Tong Y; Liu-Chen X; Ercikan-Abali EA; Capiaux GM; Zhao SC; Banerjee D; Bertino JR
J Biol Chem; 1998 May; 273(19):11611-8. PubMed ID: 9565579
[TBL] [Abstract][Full Text] [Related]
2. Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89.
Tong Y; Liu-Chen X; Ercikan-Abali EA; Zhao SC; Banerjee D; Maley F; Bertino JR
J Biol Chem; 1998 Nov; 273(47):31209-14. PubMed ID: 9813027
[TBL] [Abstract][Full Text] [Related]
3. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
[TBL] [Abstract][Full Text] [Related]
4. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake.
Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG
J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164
[TBL] [Abstract][Full Text] [Related]
5. Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase.
Landis DM; Heindel CC; Loeb LA
Cancer Res; 2001 Jan; 61(2):666-72. PubMed ID: 11212266
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Dolnick BJ; Lu K; Yin MB; Rustum YM
Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
[TBL] [Abstract][Full Text] [Related]
9. The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.
Estlin EJ; Balmanno K; Calvert AH; Hall AG; Lunec J; Newell DR; Pearson AD; Taylor GA
Br J Cancer; 1997; 76(12):1579-85. PubMed ID: 9413945
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
[TBL] [Abstract][Full Text] [Related]
11. Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells.
Shaw D; Berger FG; Spencer HT
Hum Gene Ther; 2001 Jan; 12(1):51-9. PubMed ID: 11177542
[TBL] [Abstract][Full Text] [Related]
12. Examination of the reduced affinity of the thymidylate synthase G52S mutation for FdUMP by ab initio and semi-empirical studies.
Sapse AM; Capiaux GM; Bertino JR
Mol Med; 2001 Mar; 7(3):200-4. PubMed ID: 11471557
[TBL] [Abstract][Full Text] [Related]
13. Ab initio studies of some amino acid residue complexes with 4-mercaptopyridine as a model for thymitaq (AG337), an inhibitor of thymidylate synthase.
Sapse DS; Tong Y; Bertino JR; Sapse AM
Cancer Invest; 1999; 17(6):396-401. PubMed ID: 10434950
[TBL] [Abstract][Full Text] [Related]
14. Kinetic studies on drug-resistant variants of Escherichia coli thymidylate synthase: functional effects of amino acid substitutions at residue 4.
Mahdavian E; Spencer HT; Dunlap RB
Arch Biochem Biophys; 1999 Aug; 368(2):257-64. PubMed ID: 10441376
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
[TBL] [Abstract][Full Text] [Related]
16. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies.
Webber S; Bartlett CA; Boritzki TJ; Hillard JA; Howland EF; Johnston AL; Kosa M; Margosiak SA; Morse CA; Shetty BV
Cancer Chemother Pharmacol; 1996; 37(6):509-17. PubMed ID: 8612303
[TBL] [Abstract][Full Text] [Related]
17. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase.
Reilly RT; Forsthoefel AM; Berger FG
Arch Biochem Biophys; 1997 Jun; 342(2):338-43. PubMed ID: 9186496
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
Van Triest B; Peters GJ
Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
